Marker Therapeutics (MRKR) Cash & Equivalents (2010 - 2026)

Marker Therapeutics (MRKR) has reported Cash & Equivalents for 17 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 8.93% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $14.9 million (up 8.93% YoY), while the FY2025 annual figure was $16.1 million, down 16.28% from the prior year.
• Cash & Equivalents declined to $14.9 million in Q1 2026 per MRKR's latest filing, from $16.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $28.6 million in Q1 2022 and bottomed at $6.4 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $15.4 million across 5 years, with a median of $15.1 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 77.65% — and 2025, when it surged 95.45%.
• Marker Therapeutics' Cash & Equivalents stood at $11.8 million in 2022, then grew by 28.26% to $15.1 million in 2023, then advanced by 27.01% to $19.2 million in 2024, then retreated by 16.28% to $16.1 million in 2025, then slipped by 7.17% to $14.9 million in 2026.
• Business Quant data shows MRKR's Cash & Equivalents at $14.9 million in Q1 2026, $16.1 million in Q4 2025, and $17.6 million in Q3 2025.